Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 12/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 12/20 | 0.37 |
| ▸ | WNT3A | P56704 | 2/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469168 | 0.87 | P2RX3 (0.35) | P2RX3P2RX2WNT3AMAPK1 | |
| SCHEMBL29677229 | 0.83 | P2RX3 (0.51) | P2RX3P2RX2 | |
| SCHEMBL24469153 | 0.83 | P2RX3 (0.51) | P2RX3P2RX2 | |
| SCHEMBL28671653 | 0.74 | PIK3CA (0.42) | P2RX3P2RX2 | |
| SCHEMBL29676481 | 0.74 | PIK3CA (0.42) | P2RX3P2RX2 | |
| SCHEMBL24469225 | 0.71 | P2RX3 (0.37) | P2RX3P2RX2MAPK1 | |
| SCHEMBL29677276 | 0.71 | P2RX3 (0.37) | P2RX3P2RX2MAPK1 | |
| SCHEMBL24469159 | 0.70 | MCHR1 (0.33) | WNT3AGRIA2 | |
| SCHEMBL24469169 | 0.69 | P2RX3 (0.36) | P2RX3P2RX2GRIA2 | |
| SCHEMBL29481342 | 0.67 | USP2 (0.43) | MAPK1PDE5ACHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | claimed |
| EP-4251273-B1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | claimed |
| US-20240002371-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-04 | — | — | US | claimed |
| EP-4251273-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-10-04 | — | — | EP | claimed |
| CN-116745284-A | Phthalazine derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-09-12 | — | — | CN | claimed |
| WO-2022112493-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | claimed |
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| EP-4251273-B1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | disclosed |
| US-20240002371-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-04 | — | — | US | disclosed |
| WO-2022112493-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX7 | P2RX3 1/4885P2RX2 6/4885WNT3A 443/4885 |
| US-20240002371-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX2 | P2RX3 1/4885P2RX2 3/4885WNT3A 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.